BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31721255)

  • 1. The aryl hydrocarbon receptor (AhR) as a breast cancer drug target.
    Baker JR; Sakoff JA; McCluskey A
    Med Res Rev; 2020 May; 40(3):972-1001. PubMed ID: 31721255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells.
    Loaiza-Pérez AI; Kenney S; Boswell J; Hollingshead M; Alley MC; Hose C; Ciolino HP; Yeh GC; Trepel JB; Vistica DT; Sausville EA
    Mol Cancer Ther; 2004 Jun; 3(6):715-25. PubMed ID: 15210858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AHR and GPER mediate the stimulatory effects induced by 3-methylcholanthrene in breast cancer cells and cancer-associated fibroblasts (CAFs).
    Cirillo F; Lappano R; Bruno L; Rizzuti B; Grande F; Guzzi R; Briguori S; Miglietta AM; Nakajima M; Di Martino MT; Maggiolini M
    J Exp Clin Cancer Res; 2019 Aug; 38(1):335. PubMed ID: 31370872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aryl hydrocarbon receptor: An emerging player in breast cancer pathogenesis and its potential as a drug target (Review).
    Chen C; Wang Z; Liao Z; Zhang Y; Lei W; Shui X
    Mol Med Rep; 2024 Jan; 29(1):. PubMed ID: 37997818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aryl hydrocarbon receptor activation by aminoflavone: new molecular target for renal cancer treatment.
    Callero MA; Suárez GV; Luzzani G; Itkin B; Nguyen B; Loaiza-Perez AI
    Int J Oncol; 2012 Jul; 41(1):125-34. PubMed ID: 22485252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Aryl Hydrocarbon Receptor Agonist Suppresses Migration and Invasion of Breast Cancer Cells.
    Hanieh H; Mohafez O; Hairul-Islam VI; Alzahrani A; Bani Ismail M; Thirugnanasambantham K
    PLoS One; 2016; 11(12):e0167650. PubMed ID: 27907195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AhR ligand Aminoflavone inhibits α6-integrin expression and breast cancer sphere-initiating capacity.
    Brantley E; Callero MA; Berardi DE; Campbell P; Rowland L; Zylstra D; Amis L; Yee M; Simian M; Todaro L; Loaiza-Perez AI; Soto U
    Cancer Lett; 2016 Jun; 376(1):53-61. PubMed ID: 26996297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Luteolin, an aryl hydrocarbon receptor ligand, suppresses tumor metastasis in vitro and in vivo.
    Feng J; Zheng T; Hou Z; Lv C; Xue A; Han T; Han B; Sun X; Wei Y
    Oncol Rep; 2020 Nov; 44(5):2231-2240. PubMed ID: 33000272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The aryl hydrocarbon receptor mediates raloxifene-induced apoptosis in estrogen receptor-negative hepatoma and breast cancer cells.
    O'Donnell EF; Koch DC; Bisson WH; Jang HS; Kolluri SK
    Cell Death Dis; 2014 Jan; 5(1):e1038. PubMed ID: 24481452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the aryl-hydrocarbon receptor inhibits invasive and metastatic features of human breast cancer cells and promotes breast cancer cell differentiation.
    Hall JM; Barhoover MA; Kazmin D; McDonnell DP; Greenlee WF; Thomas RS
    Mol Endocrinol; 2010 Feb; 24(2):359-69. PubMed ID: 20032195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective suppression of the human aryl hydrocarbon receptor function can be mediated through binding interference at the C-terminal half of the receptor.
    Ren L; Thompson JD; Cheung M; Ngo K; Sung S; Leong S; Chan WK
    Biochem Pharmacol; 2016 May; 107():91-100. PubMed ID: 26970402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant transformation of mammary epithelial cells by ectopic overexpression of the aryl hydrocarbon receptor.
    Brooks J; Eltom SE
    Curr Cancer Drug Targets; 2011 Jun; 11(5):654-69. PubMed ID: 21486221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AhR ligands reactivate LINE-1 retrotransposon in triple-negative breast cancer cells MDA-MB-231 and non-tumorigenic mammary epithelial cells NMuMG.
    Miret N; Zappia CD; Altamirano G; Pontillo C; Zárate L; Gómez A; Lasagna M; Cocca C; Kass L; Monczor F; Randi A
    Biochem Pharmacol; 2020 May; 175():113904. PubMed ID: 32156659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclear transport of the human aryl hydrocarbon receptor and subsequent gene induction relies on its residue histidine 291.
    Tkachenko A; Bermudez M; Irmer-Stooff S; Genkinger D; Henkler-Stephani F; Wolber G; Luch A
    Arch Toxicol; 2018 Mar; 92(3):1151-1160. PubMed ID: 29164305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of human blood levels of two PAH mixtures on the AHR signalling activation pathway and CYP1A1 and COMT target genes in granulosa non-tumor and granulosa tumor cell lines.
    Zajda K; Ptak A; Rak A; Fiedor E; Grochowalski A; Milewicz T; Gregoraszczuk EL
    Toxicology; 2017 Aug; 389():1-12. PubMed ID: 28710019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation.
    Al-Dhfyan A; Alhoshani A; Korashy HM
    Mol Cancer; 2017 Jan; 16(1):14. PubMed ID: 28103884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of inhibitory aryl hydrocarbon receptor-estrogen receptor crosstalk in human breast cancer cells.
    Safe S; Wormke M; Samudio I
    J Mammary Gland Biol Neoplasia; 2000 Jul; 5(3):295-306. PubMed ID: 14973392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aryl Hydrocarbon Receptor as an Anticancer Target: An Overview of Ten Years Odyssey.
    Hanieh H; Bani Ismail M; Alfwuaires MA; Ibrahim HM; Farhan M
    Molecules; 2023 May; 28(10):. PubMed ID: 37241719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The aryl hydrocarbon receptor in barrier organ physiology, immunology, and toxicology.
    Esser C; Rannug A
    Pharmacol Rev; 2015; 67(2):259-79. PubMed ID: 25657351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aryl hydrocarbon receptor induced intratumoral aromatase in breast cancer.
    Saito R; Miki Y; Hata S; Ishida T; Suzuki T; Ohuchi N; Sasano H
    Breast Cancer Res Treat; 2017 Feb; 161(3):399-407. PubMed ID: 27900579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.